Drug intelligence / Profile preview

EpiVacDengue Peptide vaccine

Development stage: Unknown
Lead developer: Asia Biotech Group
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

EpiVacDengue Peptide vaccine is an investigational peptide-based vaccine designed for the prevention of dengue fever. The vaccine was part of a scientific research and feasibility study project managed and invested in by Stanislav Makarenko, Ph.D., who is associated with Asia Biotech Group and ABG Pharma. It is designed to elicit an immune response against the dengue virus using peptide antigens.

Other names: EpiVacDengue

Targets

TLR2 (Toll-like Receptor 2)BCR (Immunoglobulin G B Cell Receptor)HLA-I/II (Human leukocyte antigen (HLA) class I and class II molecules)E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on EpiVacDengue Peptide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiVacDengue Peptide vaccine.

Explore the full profile